PolicyStat ID 13328827

Last Approved	3/17/2023
Effective	5/12/2023
Next Review	4/30/2024
Lines Of Business	All Lines of Business
Area	Payment Policy

COVID-19 Testing

Applicable Lines of Business:

✓ Commercial - Health Maintenance Organization (HMO), Preferred Provider Option (PPO) and Point of Service (POS)
✓ Medicare Advantage - SecureCare HMO (includes the Dual Eligible Special Needs Plan [DSNP]) and SecureChoice PPO
✓ Mountain Health Trust (MHT) including WV Medicaid (Temporary Assistance for Needy Families [TANF], Expansion [WV Health Bridge] and Supplemental Security Income [SSI] populations) and West Virginia Children's Health Insurance Program (WVCHIP)
✓ Self-Funded/Administrative Services Only (ASO)
✓ West Virginia Public Insurance Agency (WV PEIA)

Applicable Claim Type:

Dental
✓ Facility
✓ Pharmacy
✓ Professional

Definitions:

Term	Definition
Bureau for Medical Services (BMS)	BMS is the designated single state agency responsible for the administration of the State of West Virginia's Medicaid program.
Centers for Medicare and Medicaid Services (CMS)	A federal agency that provides health coverage to more than 100 million people through Medicare, Medicaid, the Children's Health Insurance Program, and the Health Insurance Marketplace.
Children's Health Insurance	The Children's Health Insurance Program (CHIP) provides low-cost

Program (CHIP)	health coverage to children in families that earn too much money to qualify for Medicaid.
Coronavirus	A kind of common virus that causes an infection in the nose, sinuses, or upper throat.
COVID-19	Coronavirus disease 2019 (COVID-19) is an infectious respiratory illness caused by a virus called SARS-CoV-2.

Policy Purpose:

The purpose of this policy is to address general payment guidelines related to COVID-19 testing as defined by The Health Plan (THP), the Centers for Medicare and Medicaid Services (CMS) and the Bureau for Medical Services (BMS) after the end of the Public Health Emergency on May 11, 2023.

Policy Description:

This policy is applicable to in-network and out-of-network providers and facilities for all of The Health Plan's (THP) Commercial, Medicare Advantage, Mountain Health Trust, Self-Funded (ASO) and WV PEIA members.

Commercial, Self-Funded/ASO, and WV PEIA Reimbursement Guidelines:

Testing will be covered at **no member cost sharing** for both in- & out-of-network providers.

Reimbursement for over-the-counter (OTC) tests will remain the same at the end of the PHE dependent on the individual benefit and/or plan documents.

See applicable covered codes for Commercial/Self-Funded/ASO/WV PEIA members in the appropriate table below.

Medicare Advantage Reimbursement Guidelines:

Individuals with traditional Medicare can continue to receive COVID-19 PCR and antigen tests with no cost sharing when the test is ordered by a physician or certain other health care providers, such as physician assistants and certain registered nurses, and performed by a laboratory. This applies to both both in- & out-of-network providers.

Reimbursement for over-the-counter (OTC) tests will remain the same at the end of the PHE dependent on the individual benefit.

See applicable covered codes for Medicare Advantage members in the appropriate table below.

Mountain Health Trust Reimbursement Guidelines:

As a result of the American Rescue Plan Act of 2021 (ARPA), states must provide Medicaid and CHIP coverage without cost sharing for COVID-19 testing through the last day of the first calendar quarter that begins one year after the last day of the COVID-19 PHE. If the COVID-19 PHE ends as expected on May 11, 2023, this coverage requirement will end on September 30, 2024.

See applicable covered codes for MHT members in the appropriate table below.

Billing Information and Guidelines:

No prior authorization is required prior to COVID-19 testing.

Providers are advised to bill the place of service code (POS) that corresponds to where the testing was performed.

Providers are advised to bill POS code 02 for drive through coronavirus testing.

Reimbursement is based upon the provider's contract.

THP Commercial, Self-Funded/ASO & WV PEIA Lines of Business (LOB)		**Code Effective Date**	**Does THP Cover?**
Code	**THP Covered Code Description**		
86328	Immunoassay for infectious agent antibody(ies), qualitative or semi quantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	4/10/2020	Yes
86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), screening	8/10/2020	Yes
86409	SARS-CoV-2 neutralizing antibody titer	8/10/2020	Yes
86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Coronavirus disease [COVID-19] antibody, quantitative	9/8/2020	Yes*
86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	4/10/2020	Yes
87426	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19]) (Coronavirus disease [COVID-19])	6/25/2020	Yes
87428	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent	11/10/ 2020	Yes

	assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; Severe Acute Respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV2 [COVID-19]) and influenza virus types A and B		
87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	3/13/2020	Yes
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [**COVID-19**]) and **influenza virus types A and B**, multiplex amplified probe technique	10/6/2020	Yes
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [**COVID-19**]), **influenza virus types A and B**, and **respiratory syncytial virus**, multiplex amplified probe technique	10/6/2020	Yes
87811	Infectious agent **antigen** detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [**COVID-19**])	10/6/2020	Yes
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus	5/20/2020	Yes
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	6/25/2020	Yes
0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed >Do not report 0224U in conjunction with 86769)	6/25/2020	Yes
0225U	The 0225U code is ePlex® Respiratory Pathogen Panel 2 by GenMark Diagnostics, Inc. The full code description is - Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected. This is an update to the ePlex Respiratory Pathogen (RP) Panel test (code 0115U) to add the SARSCoV-2 target. This is the same target addition strategy we saw with the BioFire panel 0202U. GenMark is the manufacturer and will sell the kits to providers. This test does not yet have an FDA EUA.	8/10/2020	Yes
0226U	The 0226U code is **Tru-Immune**, by Ethos Laboratories and GenScript® USA Inc. The full code description is - Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome	8/10/2020	Yes

	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum. This is a serological test that measures and also quantifies the neutralizing capacity of antibodies against the virus. This test does not yet have an FDA EUA. At this time, only ARCpoint Labs is providing specimen collection for this test.		
0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [**SARS-CoV-2**], **influenza A, influenza B**), upper respiratory specimen, each pathogen reported as detected or not detected	10/6/2020	Yes
0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [**SARS-CoV-2**], **influenza A, influenza B, respiratory syncytial virus** [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	10/6/2020	Yes
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source or just " Hopd covid-19 spec collect "	3/1/2020	Yes
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source.	3/1/2020	Yes
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, any specimen source	3/1/2020	Yes
U0001	CDC 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel U0001 is only to be used for the tests developed by the CDC using the CDC test kit. Laboratories that perform testing using a non-CDC test kit will use either CPT® code **87635** or HCPCS code U0002. Because U0001 uses a test kit obtained from the CDC, there is a lower reimbursement rate associated with this code	2/4/2020	Yes
U0002	Non-CDC 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), HCPCS code U0002 is intended for laboratories to report non-CDC laboratory tests for SARS-CoV-2/2019-nCoV (COVID-19).	2/4/2020	Yes
U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus) Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.	3/18/2020	Yes

U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R	3/18/2020	Yes
U0005	Add-on payment quick completion code. Starting January 1, 2021, laboratories can bill for the $25 add-on payment using HCPCS code U0005 if: 1) they completed the COVID-19 Clinical Diagnostic Laboratory Tests (CDLT) in 2 calendar days or less from the date of specimen collection; and 2) the majority of their COVID-19 CDLTs performed using high-throughput technology in the previous calendar month were completed in two calendar days or less for all of their patients.	1/1/2021	No

THP Medicare Advantage Line of Business (LOB)			**Does THP Cover?**
Code	**THP Covered Code Description**		
86328	Immunoassay for infectious agent antibody(ies), qualitative or semi quantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	4/10/2020	Yes
86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), screening	8/10/2020	Yes
86409	SARS-CoV-2 neutralizing antibody titer	8/10/2020	Yes
86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Coronavirus disease [COVID-19] antibody, quantitative	9/8/2020	Yes
86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	4/10/2020	Yes
87426	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19]) (Coronavirus disease [COVID-19])	6/25/2020	Yes
87428	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; Severe Acute Respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV2 [COVID-19]) and influenza virus types A and B	11/10/2020	Yes
87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	3/13/2020	Yes

	(Coronavirus disease [COVID-19]), amplified probe technique		
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [**COVID-19**]) and **influenza virus types A and B**, multiplex amplified probe technique	10/6/2020	Yes
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [**COVID-19**]), **influenza virus types A and B**, and **respiratory syncytial virus**, multiplex amplified probe technique	10/6/2020	Yes
87811	Infectious agent **antigen** detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [**COVID-19**])	10/6/2020	Yes
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus	5/20/2020	Yes
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	6/25/2020	Yes
0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed. Do not report 0224U in conjunction with 86769)	6/25/2020	Yes
0225U	The 0225U code is ePlex® Respiratory Pathogen Panel 2 by GenMark Diagnostics, Inc. The full code description is - Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected. This is an update to the ePlex Respiratory Pathogen (RP) Panel test (code 0115U) to add the SARSCoV-2 target. This is the same target addition strategy we saw with the BioFire panel 0202U. GenMark is the manufacturer and will sell the kits to providers. This test does not yet have an FDA EUA.	8/10/2020	Yes
0226U	The 0226U code is **Tru-Immune**, by Ethos Laboratories and GenScript® USA Inc. The full code description is - Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum. This is a serological test that measures and also quantifies the neutralizing capacity of antibodies against the virus. This test does not yet have an FDA EUA. At this time, only ARCpoint Labs is providing specimen collection for	8/10/2020	Yes

	this test.		
0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [**SARS-CoV-2**], **influenza A, influenza B**), upper respiratory specimen, each pathogen reported as detected or not detected	10/6/2020	Yes
0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [**SARS-CoV-2**], **influenza A, influenza B, respiratory syncytial virus** [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	10/6/2020	Yes
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source or just " Hopd covid-19 spec collect "	3/1/2020	Yes
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source.	3/1/2020	Yes
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, any specimen source	3/1/2020	Yes
U0001	CDC 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel U0001 is only to be used for the tests developed by the CDC using the CDC test kit. Laboratories that perform testing using a non-CDC test kit will use either CPT® code **87635** or HCPCS code U0002. Because U0001 uses a test kit obtained from the CDC, there is a lower reimbursement rate associated with this code	2/4/2020	Yes
U0002	Non-CDC 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), HCPCS code U0002 is intended for laboratories to report non-CDC laboratory tests for SARS-CoV-2/2019-nCoV (COVID-19).	2/4/2020	Yes
U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus) Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.	3/18/2020	Yes
U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as	3/18/2020	Yes

	described by CMS-2020-01-R		
U0005	Add-on payment quick completion code. Starting January 1, 2021, laboratories can bill for the $25 add-on payment using HCPCS code U0005 if: 1) they completed the COVID-19 Clinical Diagnostic Laboratory Tests (CDLT) in 2 calendar days or less from the date of specimen collection; and 2) the majority of their COVID-19 CDLTs performed using high-throughput technology in the previous calendar month were completed in two calendar days or less for all of their patients.	1/1/2021	No

MHT LOB (including TANF, WV Health Bridge, SSI and WVCHIP)		**Code Effective Date**	**Does THP Cover?**
Code	**THP Covered Code Description**		
86328	Immunoassay for infectious agent antibody(ies), qualitative or semi quantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	4/10/2020	Yes
86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), screening	8/10/2020	Yes
86409	SARS-CoV-2 neutralizing antibody titer	8/10/2020	Yes
86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Coronavirus disease [COVID-19] antibody, quantitative	9/8/2020	Yes
86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	4/10/2020	Yes
87426	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19]) (Coronavirus disease [COVID-19])	6/25/2020	Yes
87428	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; Severe Acute Respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV2 [COVID-19]) and influenza virus types A and B	11/10/2020	Yes

87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	3/13/2020	Yes
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [**COVID-19**]) and **influenza virus types A and B**, multiplex amplified probe technique	10/6/2020	Yes
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [**COVID-19**]), **influenza virus types A and B**, and **respiratory syncytial virus**, multiplex amplified probe technique	10/6/2020	Yes
87811	Infectious agent **antigen** detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [**COVID-19**])	10/6/2020	Yes
0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [**SARS-CoV-2**], **influenza A, influenza B**), upper respiratory specimen, each pathogen reported as detected or not detected	10/6/2020	No - TANF, WV Health Bridge, and SSI Yes- WV CHIP
0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [**SARS-CoV-2**], **influenza A, influenza B, respiratory syncytial virus** [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	10/6/2020	No - TANF, WV Health Bridge, and SSI Yes- WV CHIP
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source or just " Hopd covid-19 spec collect "	3/1/2020	Yes
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source.	3/1/2020	Yes
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, any specimen source	3/1/2020	Yes
U0001	CDC 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel U0001 is only to be used for the tests developed by the CDC using the CDC test kit. Laboratories that perform testing using a non-CDC test kit will use	2/4/2020	Yes

	either CPT® code **87635** or HCPCS code U0002. Because U0001 uses a test kit obtained from the CDC, there is a lower reimbursement rate associated with this code		
U0002	Non-CDC 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), HCPCS code U0002 is intended for laboratories to report non-CDC laboratory tests for SARS-CoV-2/2019-nCoV (COVID-19).	2/4/2020	Yes
U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus) Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.	3/18/2020	Yes
U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R	3/18/2020	Yes
U0005	Add-on payment quick completion code	1/1/2021	No - WV CHIP Yes - TANF, WV Health Bridge, and SSI
	Starting January 1, 2021, laboratories can bill for the $25 add-on payment using HCPCS code U0005 if: 1) they completed the COVID-19 Clinical Diagnostic Laboratory Tests (CDLT) in 2 calendar days or less from the date of specimen collection; and 2) the majority of their COVID-19 CDLTs performed using high-throughput technology in the previous calendar month were completed in two calendar days or less for all of their patients.		

THE CODE BELOW IS NON-COVERED, NON-REIMBURSABLE FOR ALL THP LOB:		**Code Effective Date**	**Does THP Cover?**
Code	**Code Description**		
99072	Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s) when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease	9/8/2020	No

More billing information may be found in The Health Plan's Provider Manual located at healthplan.org

"For Providers," "Resources."

Post-payment Review:

The claim and record must include documentation that reflects the criteria of this policy, and is subject to audit by THP at any time pursuant to the terms of your provider agreement.

Review/Revision History:

	Date	Action
Policy Issue Date	03/12/2021	
Date Revised	07/09/2021	Added "Effective March 12, 2021 and revised July 09, 2021" under "Policy Description." Added CPT code 87428 under the "THP Commercial, Self-Funded/ASO & WV PEIA Lines of Business (LOB)" table, the "THP Medicare Advantage Line of Business (LOB)" table and the "MHT LOB (including TANF, WV Health Bridge, SSI and WVCHIP)" table under "Billing Information."
Date Revised	7/09/2021	In the Billing and Information Guidelines section, in the table titled "THP Commercial, Self-Funded/ASO & WV PEIA Lines of Business (LOB)" changed "No" to "Yes*" under the column heading "Does THP Cover?" in reference to CPT codes: 86328, 86408, 86409, 86413, 86769, 0202U, 0223U, 0224U, 0225U and 0226U.
	7/09/2021	Added "*Claims must be submitted with medical records indicating medical necessity when billing this CPT code. **Claims submitted without medical records will deny "RI" (required documentation not attached)" after** the table titled "THP Commercial, Self-Funded/ASO & WV PEIA Lines of Business (LOB)" in the Billing and Information Guidelines section.
Annual Review	5/9/2022	Changed coverage for U0005 from 'Yes" to "No" for all LOB, except for TANF, WV Health Bridge, and SSI. Changed 0240U and 0241U to "No" for TANF, WV Health Bridge, and SSI, and "Yes" for WV CHIP. Reviewed criteria, updated references and links.
Annual Review	2/22/23	Removed "*" and "*Claims must be submitted with medical records indicating medical necessity when billing this CPT code. **Claims submitted without medical records will deny "RI" (required documentation not attached)"** from table titled "THP Commercial, Self-Funded/ASO & WV PEIA Lines of Business (LOB)" in the Billing and Information Guidelines section. Reviewed and updated references and links.
Revision	3/7/2023	Updated the Policy Purpose to include guidelines defined by The Health Plan, as well stating that this policy relates to COVID-19 testing after the PHE. Removed "The Health Plan (THP) is following the measures related to COVID-19 testing instituted by CMS and BMS during the coronavirus (COVID-19) pandemic" from the Policy Description section. Combined

		Commercial, ASO/Self-Funded, and WV PEIA Guidelines, removed previous criteria, and added the following statements to that section: "Testing will be covered at no member cost sharing for both In- & Out-Of-Network providers. Reimbursement for over-the-counter (OTC) tests will remain the same at the end of the PHE dependent on the individual benefit and/or plan documents." Removed previous criteria and adding the following to the Medicare Guidelines section: "Individuals with traditional Medicare can continue to receive COVID-19 PCR and antigen tests with no cost sharing when the test is ordered by a physician or certain other health care providers, such as physician assistants and certain registered nurses, and performed by a laboratory. This applies to both both in- & out-of-network providers. Reimbursement for over-the-counter (OTC) tests will remain the same at the end of the PHE dependent on the individual benefit and/or plan documents." Updated references.

References and Research Materials:

American Medical Association. New CPT codes for multi-virus tests detect COVID-19 and flu. October 7, 2020. https://www.ama-assn.org/press-center/press-releases/new-cpt-codes-multi-virus-tests-detect-covid-19-and-flu

West Virginia Department of Health and Human Services, Bureau for Medical Services. CY 2022 Clinical Lab Fee Schedule. Accessed May 16, 2022. https://dhhr.wv.gov/bms/FEES/Pages/Clinical-Diagnostic-Lab-Fee-Schedules.aspx

American Medical Association. AMA releases 2021 CPT code set. September 1, 2021. https://www.ama-assn.org/press-center/press-releases/ama-releases-2021-cpt-code-set

Centers for Medicare and Medicaid (CMS). What do I need to know? CMS Waivers, Flexibilities, and the Transition Forward from the COVID-19 Public Health Emergency. Published February 27, 2023. Accessed February 28, 2023.

United States Food and Drug Administration. FAQs: What happens to EUAs when a public health emergency ends? Updated January 31, 2023. Accessed February 28, 2023.

United States Department of Health and Human Services. Fact Sheet: COVID-19 Public Health Emergency Transition Roadmap. Published February 9, 2023. Accessed February 28, 2023.

Disclaimer:

This policy is intended to provide a general reference regarding billing, coding and documentation guidelines. Coding methodology, regulatory requirements, industry standard claims editing logic, benefit design and other factors are considered in developing payment policies. This policy is intended to serve as a guideline only and does not constitute medical advice, any guarantee of payment, plan pre-authorization, an explanation of benefits, or a contract. This policy does not govern whether a specific procedure is covered under any specific member plan or policy, nor is it intended to address every claim situation. The determination that any service, procedure, item, etc., is covered under a member's benefit plan shall not be construed as a determination that a provider will be reimbursed for services provided. Individual claims

may be affected by other factors, including but not necessarily limited to state and federal laws and regulations, legislative mandates, provider contract terms, and THP's professional judgment. Reimbursement for any services shall be subject to member benefits and eligibility on the date of service, medical necessity, adherence to plan policies and procedures, claims editing logic, provider contractual agreement, and applicable referral, authorization, notification and utilization management guidelines. Unless otherwise noted within the policy, THP's policies apply to both participating and non-participating providers and facilities. THP reserves the right to review and revise these policies periodically as it deems necessary in its discretion, and it is subject to change or termination at any time by THP. THP has full and final discretionary authority for its interpretation and application. Accordingly, THP may use reasonable discretion in interpreting and applying this policy to health care services provided in any particular case.

All Revision Dates

3/17/2023, 6/17/2022, 7/30/2021, 3/9/2021, 2/18/2021

Attachments

COVID 19 Specimen Billing Instructions Update 12.04.2020.pdf

COVID_FFS-Inclusive_FAQs-updated_12.16.2020_0.pdf

New CPT codes for multi-virus tests detect COVID-19 and flu.pdf